List of Studies ( Metabolite:3-Propylmalic acid)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004291 | AN007136 | Metabolomics analysis of Plasmodium falciparum asexual-stage parasites treated with plasmepsin V peptidomimetics - 16 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004290 | AN007134 | Metabolomics characterisation of Plasmodium falciparum response to plasmepsin V peptidomimetic inhibitors - 5 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004190 | AN006961 | Comparative Analysis of the Metabolic Profiles of Alix−/− and Ozz−/− Soleus Skeletal Muscle | Muscle | Mouse | St Jude Children's Research Hospital | LC-MS | |
| ST004153 | AN006894 | Multi-omics Study of Small Intestine Adaptation After Total Colectomy in a Rat model | Feces | Rat | Shanghai Jiao Tong University | LC-MS | |
| ST003655 | AN006005 | Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via GPR84 receptor | Blood | Human | Cancer | Universitätsspital Zürich | MALDI-MS |
| ST003655 | AN006005 | Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via GPR84 receptor | Blood | Mouse | Cancer | Universitätsspital Zürich | MALDI-MS |
| ST003565 | AN005858 | Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003521 | AN005783 | Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii | Bacterial cells | Acinetobacter baumannii | Bacterial infection | Monash University | LC-MS |
| ST003179 | AN005222 | Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003160 | AN005185 | New class of heterospirocyclic compounds present strong and rapid activity against artemisinin- and multidrug-resistant P. falciparum parasites | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003036 | AN004978 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | LC-MS |
| ST002309 | AN003772 | Targeting malaria parasites with novel derivatives of azithromycin | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002066 | AN003366 | Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer | Lung | Mouse | Cancer | Walter and Eliza Hall Institute of Medical Research | LC-MS |
| ST001315 | AN002190 | Retargeting azithromycin-like compounds as antimalarials with dual modality | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001276 | AN002117 | Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | LC-MS |
| ST001274 | AN002115 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | LC-MS |
